TL;DR
This study investigated the link between high-density lipoprotein (HDL) cholesterol levels and mortality in patients with heart failure and coronary heart disease. They found that higher HDL cholesterol was associated with significantly lower all-cause mortality, even after accounting for various clinical factors. This suggests that HDL cholesterol might play a protective role in this vulnerable patient population.
What Problem Does This Paper Address?
Heart failure (HF) is a major cause of death worldwide, and coronary heart disease (CHD) is a primary driver of HF. Despite advancements in treating CHD, patients with reduced ejection fraction heart failure (EFrHF) complicating CHD still face a very high mortality rate. While HDL cholesterol is known for its cardio-protective effects in CHD, its specific role in the prognosis of EFrHF patients with concurrent CHD was unclear. This paper aims to fill that knowledge gap by examining the association between HDL cholesterol levels and all-cause mortality in this specific patient group.
Methods
The researchers conducted a retrospective observational study. They recruited 323 patients who had been diagnosed with both CHD (confirmed by angiography) and EFrHF (defined as left ventricular ejection fraction (LVEF) ≤35% via echocardiography). Patients were categorized into "low HDL" and "high HDL" groups based on the National Cholesterol Education Program (NCEP) ATP III criteria (≤1.03 mmol/L for low HDL). They collected demographic, medical, and laboratory data and followed up to determine all-cause mortality as the primary endpoint. Statistical analyses included t-tests, Mann-Whitney U tests, chi-square tests, Pearson and Spearman correlations, and univariate and multivariate logistic regression to assess the associations between HDL cholesterol and mortality, while controlling for numerous confounding variables.
Datasets
The study utilized data from the Medical Document System of Guangdong General Hospital, collected between 2010 and 2015. This dataset comprised 323 patients who met the inclusion criteria for CHD and EFrHF. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- HDL Cholesterol as a Potential Protective Factor: The most striking finding is the independent association between higher HDL cholesterol and improved survival in a high-risk patient group. This challenges the notion that all lipid components are detrimental in HF.
- Broader Lipid Profile Differences: Patients with higher HDL also tended to have higher levels of total cholesterol (TC), LDL cholesterol, and ApoA1, suggesting that it's not just about "lowering everything" in HF, but potentially about the balance and specific roles of different lipids.
- Inflammation and Liver Function Links: The inverse correlation between HDL cholesterol and markers of inflammation (Hs-CRP) and liver function (ALT) is significant. This hints at potential mechanisms by which HDL might exert its protective effects, possibly by dampening inflammation and supporting metabolic health.
- Nutritional Status Connection: The positive correlation with albumin (ALB), a marker of nutritional status, suggests that higher HDL might be indicative of better overall health and nutritional reserves in these patients.
Key Results
- Patients in the high HDL cholesterol group had a significantly lower mean mortality rate (43.5%) compared to the low HDL group (59.1%) (P=0.007).
- After extensive adjustments in multivariate regression analysis, higher HDL cholesterol remained significantly associated with a reduced risk of all-cause mortality, with an odds ratio of 0.007 (95% CI 0.001-0.327, P=0.012) in the final model.
- HDL cholesterol was positively correlated with albumin (ALB) (r=0.248, P<0.001) and inversely correlated with alanine aminotransferase (ALT) (r=-0.146, P=0.013), high-sensitivity C-reactive protein (Hs-CRP) (r=-0.207, P=0.003), and NYHA classification (r=-0.161, P=0.004).
- Survivors had significantly higher HDL cholesterol (1.00±0.30 mmol/L vs 0.89±0.25 mmol/L, P=0.001) and ApoA1 levels compared to non-survivors.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: This study cannot establish a causal relationship between HDL cholesterol and mortality; it can only show an association.
- Medication Data: Long-term medication usage data was not fully captured or adjusted for, which could influence outcomes.
- Body Mass Index (BMI) and Body Weight: Data on BMI and body weight were lacking, and these factors are known to be closely correlated with lipid profiles, potentially leading to over- or under-estimation of the HDL-mortality association.
- Endpoint Specificity: The study relied on all-cause mortality as the sole endpoint due to difficulties in accurately recalling specific clinical events and their dates.
Future work should focus on prospective studies to confirm these findings and explore whether interventions aimed at increasing HDL cholesterol levels can indeed improve survival in patients with EFrHF complicating CHD.
Summary updated